Product Description
EPOK Therapeutics’ lead candidate, EPRA-0322, is a mono-specific antibody with potent erythropoietin receptor agonist activity currently in GMP cell-line development. Pre-clinical studies demonstrated the potential for low (<1 ug /kg), 4 - 6 doses a year subcutaneous dosing in humans, and low cost of goods. Moreover, unlike the approved anemia treatment agents, EPRA-0322 does not activate other human receptors, which may offer a better safety profile. (Sourced from: https://www.epoktherapeutics.com/focus-pipeline)
Mechanisms of Action: EPO Agonist
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: EPOK Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Anemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|